Stereotaxis Reports Q3 2025 Financial Results with $7.5M Revenue, Expects Continued Growth.

Stereotaxis reported Q3 2025 financial results with revenue at $7.5 million, up from $4.4 million in the prior year. System revenue was $1.9 million, while recurring revenue reached $5.6 million. Gross margin was 55%, with recurring revenue gross margin at 67% and system gross margin at 19%. Operating expenses were $10.7 million, including $4.1 million in non-cash charges. The company's commercial progress includes two Genesis robotic system orders and FDA clearance for the GenesisX robotic system.